CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases,…

Read more

CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer

A new collaborative research project has now been initiated, which may be used to validate rare genetic causes of neurogenerative diseases as…

Read more

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 22, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

Read more

CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 08, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), a commercial-stage company…

Read more

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creation

CAMBRIDGE, Mass. and ROSTOCK,…

Read more

CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan

  • Enables refocusing on core business of delivering valuable, data-driven insights to patients, and pharmaceutical companies globally
  • EUR 15 million…

Read more

CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer

Dr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successor

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN,…

Read more

CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development

  • CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AI
  • …

Read more

CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World

  • The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and…

Read more

CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery

Leveraging AI to Accelerate the Path From Diagnosis to Cure

Read more

For Further Inquiries Please Contact

Press Contact

Melissa Hall

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads